Tildrakizumab Real-World Effectiveness and Safety Over 64 Weeks in Patients With Moderate-to-Severe Plaque Psoriasis.
Jayme HeimJ Gabriel VasquezTina BhutaniJohn KooJacob MathewRanga GogineniThomas FerroNeal Bhatia
Published in: Journal of drugs in dermatology : JDD (2024)
Tildrakizumab treatment was effective in adult patients with moderate-to-severe plaque psoriasis in real-world settings, with no new safety signals. J Drugs Dermatol. 2024;23(8):612-618. doi:10.36849/JDD.8217.